UNSPSC 51123110: Ibutilide

This classification denotes a cation channel blocker and antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 2436VX1U9B. European Medicines Agency schedules Ibutilide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08102MIG. Ibutilide generally arises in the molecular formula C20H36N2O3S.

UNSPSC 51123110 Ibutilide is a Commodity code encompassing injectable pharmaceutical products used in advanced life support and emergency medical care. State and local governments procure ibutilide and related antiarrhythmic medications primarily through emergency medical services departments, fire rescue agencies, and regional hospital systems for use in acute cardiac care protocols. The City of Tampa Fire Rescue, Texas Health and Human Services Commission, and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of issuing bodies active in this space—ranging from municipal emergency services to state health agencies and cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. Procurement under this code involves sealed competitive bidding for specific unit quantities with firm pricing, expedited delivery timelines (often ten calendar days), strict expiration-date requirements (typically nine months or more from acceptance), and compliance with OSHA Hazard Communication Standards and FDA manufacturing requirements.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications with a due date of April 8, 2026, requesting 1,020 units of Diltiazem alongside other cardiac agents for Tampa Fire Rescue, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in early April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, signaling exploratory procurement strategy before formal RFP issuance. The Minnesota Department of Administration, through MMCAP, issued an RFP (S1070000015802) with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with awards effective July 1, 2026. Vendors must maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), certify cGMP and Drug Supply Chain Security Act compliance, and carry comprehensive insurance including $5 million commercial general liability coverage.